Sign up USA
Proactive Investors - Run By Investors For Investors

M Pharmaceutical hires Maxim Group to help with growth strategy

"We chose to partner with the Maxim Group because of their successful track record..." said M Pharma
M Pharmaceutical hires Maxim Group to help with growth strategy
M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity and weight management.

Drugs and treatment group M Pharmaceutical Inc (CNSX:MQ) has hired New York based Maxim Group to help it execute its growth strategy.

It will act as the firm's corporate finance adviser, in particular related to developing a financial strategy to restructure its current debt facilities and to act as lead adviser for possible future debt and equity financings.

"We chose to partner with the Maxim Group because of their successful track record as a respected, full-service investment banking firm and look forward to their advice and guidance with respect to our important strategic decisions," said Gary A. Thompson, president and chief executive officer of M Pharma.

"Their health care team will be an invaluable partner in the execution of our growth strategy."

The agreement began on April 1 this year and Maxim will receive on the first day of each month of the six-month term US$7,500.

The agreement also entitles Maxim to specific success-based compensation, along with 4.5 million M Pharma shares.

M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity and weight management.

It has two potential blockbuster products: a side-effect-free version of the best-selling slimming product orlistat (probably better known to consumers as Xenical) and a female sexual dysfunction (FSD) remedy.

Add to that an infertility treatment and a handful of other revenue-generating products and you have a diversified healthcare business with significant blue-sky potential.

It is scheduled to launch its FDA -cleared fertility product branded as 'ToConceive' some time in the second quarter of 2017, it said.

Giles_55af4ddca6481.jpg
Why Invest In M Pharmaceutical? Read More Here

Register here to be notified of future MQ Company articles
View full MQ profile View Profile

M Pharmaceutical Timeline

Related Articles

shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
shutterstock_139366595.jpg
January 25 2017
The company's update reveals a company in rude health
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 12 2017
Richard Lipscombe talked revenue generation and growth path with investors.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use